PSMD9

Across TCGA pan-cancer cohorts, PSMD9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMD9 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PSMD9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PSMD9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where PSMD9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.960	0.695	<.001	27	view →
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	10	view →
UCEC	DFS	Median	II,III,IV	0.919	0.529	.014	8	view →
CCRCC	DFS	Quartile	II,III,IV	0.510	0.803	.030	6	view →
LSCC	DFS	Quartile	All	1.000	0.891	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMD9–HNSC (DFS)

Open the HNSC breakdown →